Loading...
•
Dec 31, 2023
Novocure Q4 2023 Earnings Report
Novocure's financial performance for Q4 2023 showed revenue growth, offset by increased operating expenses, resulting in a net loss.
Key Takeaways
Novocure reported a 4% year-over-year increase in total net revenues for Q4 2023, reaching $133.8 million. The company experienced a net loss of $47.1 million, or $0.45 per share. Key markets including the United States, Germany, and Japan contributed significantly to the quarterly revenue.
Total net revenues for the quarter were $133.8 million, a 4% increase year-over-year.
The United States, Germany and Japan contributed $91.3 million, $14.7 million, and $7.6 million in quarterly net revenues, respectively.
Net loss for the quarter was $47.1 million with loss per share of $0.45.
As of December 31, 2023, there were 3,755 active patients on therapy, an increase of 9% year-over-year.
Revenue by Geographic Location
Forward Guidance
2024 will be a pivotal year for Novocure, with a focus on growing the GBM business, launching TTFields therapy in non-small cell lung cancer, and delivering on clinical and product development pipelines.
Positive Outlook
- Growing GBM business
- Launching TTFields therapy in non-small cell lung cancer
- Delivering the promise of our clinical trial
- Product development pipelines
- Achieving our goals should position Novocure for sustained success for years to come.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...